Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03VPC
|
|||
| Former ID |
DAP000191
|
|||
| Drug Name |
Cilostazol
|
|||
| Synonyms |
cilostazol; 73963-72-1; Pletal; Cilostazole; Pletaal; Cilostazolum; OPC-13013; Cilostazolum [INN-Latin]; OPC-21; OPC 13013; OPC 21; UNII-N7Z035406B; CHEBI:31401; C20H27N5O2; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; BRN 3632107; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; MLS000028470; Cilostazole; Otsuka brand of cilostazol; C 0737; CL23867; Cilostazol [INN:JAN]; Pleta (TN); Pletal (TN); Pletal, Cilostazol; Cilostazol (JP15/USAN/INN); 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Intermittent claudication [ICD-11: BD40.00; ICD-9: 440.21] | Approved | [1], [2] | |
| Therapeutic Class |
Vasodilator Agents
|
|||
| Company |
Otsuka Pharmaceutical Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H27N5O2
|
|||
| Canonical SMILES |
C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
|
|||
| InChI |
1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
|
|||
| InChIKey |
RRGUKTPIGVIEKM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 73963-72-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
855683, 6897916, 7848958, 7978527, 8151779, 11110906, 11113335, 11372358, 11374323, 11484992, 11488934, 11490985, 11492587, 11528739, 12012700, 14755273, 14828756, 17404781, 24278291, 26612838, 26680450, 26719653, 26719654, 26746958, 26746959, 29221909, 46386747, 46386994, 46506317, 47365365, 48259412, 48259413, 49834949, 50100194, 50103999, 50104000, 50409718, 53777324, 53787948, 56422089, 56463107, 57321435, 68530811, 85230957, 85787626, 87218800, 87218801, 87219014, 90341176, 92124839
|
|||
| ChEBI ID |
CHEBI:31401
|
|||
| ADReCS Drug ID | BADD_D00466 | |||
| SuperDrug ATC ID |
B01AC23
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 3 (PDE3) | Target Info | Modulator | [3] |
| Phosphodiesterase 3A (PDE3A) | Target Info | Inhibitor | [4] | |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Morphine addiction | ||||
| Reactome | cGMP effects | |||
| G alpha (s) signalling events | ||||
| WikiPathways | miR-targeted genes in muscle cell - TarBase | |||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7148). | |||
| REF 2 | Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
| REF 4 | A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.